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Policy Forum
“O
ur Special Projects 
Division produces a wide 
portfolio of therapy and 
topic-speciﬁc materials…available 
for sponsorship by companies who 
wish to promote their products or 
services, while visibly supporting 
nurse education,” [1] invites Nursing
Standard, the journal of the United 
Kingdom Royal College of Nursing. 
The commercial sponsorship of 
nursing education exempliﬁed by 
this advertisement reﬂects the fact 
that nurses have increasing power to 
choose products and services, and to 
inﬂuence choices made by medical 
and other colleagues [2]. Prescription 
pharmaceuticals provide a notable 
example of how nurses have become, as 
proclaimed above, a desirable target for 
a powerful industry.
This industry has been robustly 
critiqued in the medical literature 
for exploiting patients and doctors 
using a range of techniques: direct-to-
consumer advertising (DTCA) [3–6], 
sponsored teaching materials [7], 
advertising in professional media [8,9], 
research funding [10–14], ghost writing 
[15,16], gifts, free meals, and travel 
[7,13,17].
The nursing literature has yet to 
pay much attention to the expansive 
reach of the pharmaceutical industry 
into the nursing profession. In this 
article, we examine some of the key 
literature on the inﬂuence of drug 
companies upon nurses, consider the 
limitations of this literature, and deﬁne 
a strategy for heightening awareness 
and strengthening the skills of nurses 
to manage the impact of commercial 
interests.
Our Literature Search
We searched MedLine (http://www.
ncbi.nlm.nih.gov/pubmed/) and 
CINAHL (http://www.cinahl.com/
prodsvcs/cinahldb.htm) databases 
without date restriction in May 2007, 
using the terms “pharmaceutical 
industry,” “drug sales,” “direct-to-
consumer,” and “pharmaceutic*,” 
and restricted to nursing journals. We 
searched the same terms without the 
nursing journal restriction, combined 
with the truncated search terms “nurs*” 
and prescri*.” A search combining 
the term “nurs*” with “gift,” a hand 
search, and references from colleagues 
completed our research. 
We included all articles making 
reference to nursing’s relationship 
to drug companies and those that 
included the perspectives of the 
pharmaceutical industry on this issue. 
As our intention was to understand the 
ﬁeld, we examined all types of articles, 
from empirical research papers to pure 
opinion.
We found 32 articles that met our 
inclusion criteria. Of these, seven 
were empirical studies (summarised in 
Table 1), two were theoretical, using 
anthropological or ethical frameworks 
to describe the implications of the gift 
exchange, and 23 were perspectives, 
commentaries, opinions, and non-
systematic (narrative) reviews. There 
were 16 articles from nursing journals, 
nine from nurse practitioner journals, 
two from medical journals, and ﬁve 
from multi-disciplinary journals.
From these 32 articles, we identiﬁed 
and grouped topics and concerns, and 
positioned them relative to debates 
in the medical literature about the 
inﬂuence of the pharmaceutical 
industry upon patient and professional 
education, gift giving, DTCA, provision 
of free drug samples, and other 
determinants of prescribing practice. 
Our Findings
Balance of criticism versus support. 
Given the vociferous debate in the 
medical literature, we anticipated 
positioned papers that would take clear 
stances for or against the involvement 
of the pharmaceutical industry in the 
nursing profession. Such a dichotomy 
was not evident in the articles we 
located. Of the 32 articles, 13 expressed 
or reported serious concerns about the 
role of the pharmaceutical industry, 
and four were clearly industry-friendly; 
these are explored in greater depth in 
Table 2. The remaining publications 
either expressed mild concern about 
the pharmaceutical industry, viewed 
the support of the industry as generally 
favourable, or identiﬁed both the 
harms and beneﬁts of the industry’s 
involvement in health care.
Direct-to-consumer advertising.
Seven articles address DTCA, three 
of these providing overviews and 
identifying consequent problems for 
patient–clinician communication. 
The overviews draw upon the medical 
literature, and lament the scant 
research available to assess the impact 
of DTCA on nurses [18–20], but 
offer limited criticism. One of these 
overviews focused on presenting a 
balanced report of the beneﬁts and 
harms of DTCA, presenting a number 
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of arguments both for and against 
the practice, but concluding with the 
view that DTCA might beneﬁt patients 
by prompting them to seek medical 
attention, and suggesting that a 
“balance” is required [19].
An opinion piece, written by health 
advocate Charles Inlander for a nursing 
economics journal, praises DTCA as an 
antidote to medicine’s self-interested 
reluctance to share information [21]. 
Another, written by employees of the 
industry, speaks of guarding the line 
between promotion and education, 
but not surprisingly concludes that 
the industry has an important role 
to play in patient education—one 
that these authors hope will expand 
[22]. Three articles encourage health 
care professionals to work with the 
pharmaceutical industry to promote 
accurate patient information, and 
not to be predisposed against DTCA 
[20,23,24].
Professional education. Many of the 
articles (ten out of 31) draw attention 
to the substantial role that information 
from the pharmaceutical industry plays 
in the education of nurses [22,25–33]. 
Sponsored professional education, 
drug samples and information, small 
gifts, and patient services are portrayed 
as beneﬁcial, even though caution 
is advised in their use—unethical 
behaviour is cast as possible, but 
exceptional [28,34]. Lynore DeSilets, 
a nursing educator, recommends 
robust professional guidelines and 
accreditation as safeguards [27]. 
Samples and gifts from, or 
contacts with, pharmaceutical sales 
representatives. Fifteen of the 
articles consider pharmaceutical 
sales representatives (PSRs) and/or 
their provision of drug samples to 
prescribing nurses. In an advice 
column to nurse practitioners (NPs), 
lawyer Cathy Klein acknowledges 
evidence that provision of samples 
inﬂuences medical prescribing, 
and increases rather than decreases 
costs, but also views pharmaceutical 
representatives as an important source 
of practical guidance and information 
for nurses [35]. Bambi Alexander-
Banys, in a guest editorial for the 
Journal of Pediatric Health Care, starts by 
acknowledging and appreciating the 
pharmaceutical industry’s support of 
NPs, and then criticises the industry for 
failing to court NPs or make reference 
to them in DTCA as they do doctors. 
This, the author suggests, reinforces 
traditional perceptions of the latter as 
the credible provider of patient care, to 
the detriment of the NP role [36]. 
In an editorial exchange in The
Nurse Practitioner, student family nurse 
practitioner Sarah Sidiqi argues that 
NPs may be unwitting victims of the 
pharmaceutical industry’s commercial 
agenda [37], but receives a sceptical 
response from the editor, who 
questions the evidence that NPs have 
been approached inappropriately in 
the ways that doctors have, and points 
out that NPs are generally ignored by 
the industry [38]. A pilot interview 
study of six NPs found that all believed 
pharmaceutical companies inﬂuenced 
their prescribing, with both positive 
and negative consequences [31]. A 
survey of 221 oncology NPs found that 
over half (57%) of respondents viewed 
the provision of sample drugs as having 
affected their prescribing choice [24]. 
Many articles conclude that small gifts 
from PSRs are acceptable. Jill Davies 
and Steve Hemingway, both nursing 
educators, suggest such gifts should 
not exceed UK£5 (~US$10) [26], 
while an editor of The Nurse Practitioner,
Marilyn Edmunds, as well as clinical 
nurse specialist Patricia O’Malley, see 
US$100 as the top range for such gifts 
[28,39]. Not surprisingly, a “medical 
writer” with “12 years’ experience in 
pharmaceutical sales training” writing 
in Advance for Nurse Practitioners refers to 
promotional objects as a normal part of 
professional practice and fails to offer 
any critical consideration of the gift or 
its consequences [29]. Melodie Young, 
president of the Dermatology Nurses’ 
Association, mirrors this approach in 
Table 1. Summary of Empirical Findings Regarding Pharmaceutical Industry Inﬂuence on Nurses
Methodology Sample Findings Reference
Survey: 35-item 
questionnaire
347 MHNs
(76 male)
u 290 (84%) accepted PSRs meeting with clinical teams
u 161 (46%) accepted PSRs meeting with individual MHNs
u 3 (8.6%) agreed that MHNs should not attend events focusing on speciﬁc drugs
u 305 (88%) not opposed to receiving information and gifts
u 67 (19%) believe the clinical environment should be free of “gifts”
[40]
Survey: 12-question 
questionnaire
221 NPs u 82%a believed DTCA provides “patient education”
u 94%a had patient requests resulting from DTCA
u 57%a believed samples from PSRs affected their prescribing decisions
u 52%a did not feel “pressured” to prescribe in response to patient requests
[24]
Survey 91 nurse prescribers u 50%a stated that information from industry had inﬂuenced their prescribing [66]
Survey: 14-item 
questionnaire
51 MHNs
(8 male)
u A “majority”a never had formal guidance regarding interaction with PSRs
u PSRs said to provide a variety of services “valued” by respondentsa
[33]
Semi-structured interview 22 nurse prescribers u 11 (50%) used representatives from industry as source of prescribing information [30]
Survey: 55-item 
questionnaire (also 
administered to medical 
and pharmacy students for 
comparison)
17 NP students
(2 male)
u Poor knowledge of both industry marketing (average 2.9/10 multiple-choice questions correct) 
 and professional ethics (average 9/16 true/false questions correct)
u Frequent interaction with PSRs (average 10.4 contacts per month); considerable use of and
 conﬁdence in information provided by PSRs; general willingness to accept and use drug samples 
 from PSRs for both clinical and personal use 
[32]
Interview 6 NPs u 4 (67%) believed that free samples might inﬂuence their choice of prescription 
u 4 (67%) got information from PSRs
u 6 (100%) had attended industry-sponsored conferences
u 5 (83%) had accepted gifts
[31]
aRaw data not provided.
MHN, mental health nurse.
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her article, which promotes PSRs as 
providing important support for nurses 
in Dermatology Nursing [34]. 
Michael Monaghan and colleagues 
used a cross-sectional survey to 
determine that NP students (n = 17) 
had both more positive attitudes 
towards PSRs and more contact with 
them than pharmacy students (n = 
54) [32]. Similarly, in a large survey of 
mental health nursing students at two 
universities in the United Kingdom, 
88% (305 out of 347) believed it was 
acceptable to receive some form of 
gift from industry [40]. Over half 
(57%) of the students believed that 
pharmaceutical representatives did not 
always give unbiased information, but 
thought that they and mental health 
nurses in general would be able to 
detect any bias. Only 20% believed 
that the clinical environment should 
be free of promotional objects. A study 
of 51 psychiatric nurses reported that 
an unspeciﬁed “majority” had received 
no guidance about working with the 
pharmaceutical industry [33]. 
Three industry-friendly articles 
[22,29,34], two of which were written 
by previous or current employees of 
the pharmaceutical industry [22,29], 
applaud the role of PSRs, noting their 
role in education. Whilst the authors’ 
history of working for industry is 
described, this history is presented 
as a credential for, rather than risk 
to, the credibility of their claims. 
Willis, in an article on career options, 
recommends the pharmaceutical sales 
force as a career option for nurses and 
uncritically equates pharmaceutical 
sales to promoting solutions to patients 
[41].
Concern about the pharmaceutical 
industry. Thirteen of 31 articles express 
or report unequivocal concerns about 
the risks to practice presented by the 
pharmaceutical industry. Nursing 
professor Lisa Day’s theoretical 
discussion of gift exchange argues 
that any gift, however small, places 
an obligation on recipients, resulting 
in unwanted debt. Such debt may 
be repaid by prescribers and those 
inﬂuencing them [42].
A similarly critical view of the 
industry is apparent in two general 
news articles reporting current 
events and describing concerns 
about drug companies’ inﬂuences 
on nurses, voiced by a union leader 
in the ﬁrst article, and by a range 
of nursing, pharmacy, and medical 
experts speaking to the UK House 
of Commons about drug company 
marketing strategies in the second 
[43,44]. Lecturers in mental health 
nursing Russell Ashmore and Neil 
Carver are particularly sceptical about 
supposed beneﬁts of information 
provided by industry, and point 
out that mental health nurses 
may be particularly vulnerable to 
pharmaceutical company advertising 
and “clinical support” [18,40]. Nurse 
ethicist Nancy Crigger’s assessment 
of pharmaceutical promotion and NP 
decision making offers a critique of the 
industry, and argues for guidelines to 
reduce potential harms, but is diluted 
by PSR Larry Bennison’s counter-
argument in the same article [45]. 
Four nonsystematic narrative 
reviews address nursing education, 
and how guidelines and professional 
responsibilities may help to shift 
nursing education from commercial 
to professional sources of information 
[26,39,46,47]. Many of these articles 
point out the ethical challenges 
of pharmaceutical gift giving but 
offer few, if any, solutions. There 
is a comfortable sense that nurses, 
once alerted, will not be “caught” by 
marketing practices, that skills central 
to the nursing profession inherently 
provide nurses with the ability to 
evaluate information effectively 
[26,46], that ethics committees will 
give adequate guidance [48], and that 
guidelines or codes will prevent the 
problem [47,49]. A strongly worded 
debate between a sceptical NP and a 
PSR concludes with vague references to 
guidelines and raising awareness [45]. 
Sidiqi’s letter to the editor of The Nurse 
Practitioner is just as strongly worded, 
but similarly, is quickly deﬂated by the 
editor’s comments about NPs being 
unlikely to get “caught” in the same way 
as doctors [37,38].
Remarkably, none of the articles 
from the nursing literature reviewed 
here included author disclosure about 
possible competing interests. Over 
the past two decades, medical journals 
have increasingly required authors to 
Table 2. Summary of Article Positions and Competing Interests
Article Type N Competing Interestsa Overall Sympathy with Pharmaceutical Industry
Editorial/commentary/perspective 9 none declared u 2 ++ 
u 3 +/-
u 2 - 
u 2 --
News feature 5 1 employee; 
4 none declared 
u 1 ++ (previous employee)
u 1 +
u 1 +/-
u 2 --
Non-systematic review 7 1 employee; 
6 none declared 
u 1 ++ (employee)
u 5 +/-
u 1 --
Survey 7  none declared u 2 +/-
u 2 Ø
u 3 --
Theoretical 2 none declared u 2 --
Other 2 none declared u 1 +/-
u 1 --
++, views inﬂuence of pharmaceutical industry in very positive light; +, views inﬂuence of pharmaceutical industry as generally favourable; +/-, identiﬁes both harms and beneﬁts of 
pharmaceutical company inﬂuence; -, concerns about industry inﬂuence; --, grave concerns about industry inﬂuence; Ø, no position identiﬁed.
aIn two cases there was evidence that authors were employed by a pharmaceutical company. Otherwise there was no disclosure of competing interests in any of the 32 surveyed articles.
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declare competing interests, as these 
are recognised as potential sources 
of bias in the collection, analysis, and 
interpretation of data [50]. As we have 
seen, nurses are subject to many of the 
same conﬂicts of interest as doctors, yet 
the nursing literature lacks even this 
most basic means of detecting possible 
bias.
Discussion
Nursing education fails to prepare 
graduates to deal with pharmaceutical 
promotion. From the scant empirical 
work available, many nurses would 
appear to accept promotional material 
uncritically. Nurses, just like doctors, 
might beneﬁt from understanding 
marketing and persuasion [51]. 
Nurses should be encouraged to 
re-evaluate the educational beneﬁts 
of promotional information, which 
is carefully selected, prone to bias, 
and hardly likely to be as beneﬁcial 
as many believe [52,53]. Similarly, 
they should reconsider the presumed 
educational beneﬁt and lack of bias in 
DTCA, as these presumptions have now 
been widely refuted [54–56]. Rather 
simplistically, many articles about 
nurses and DTCA have announced 
that nurses must be “cognizant” or 
“aware”—suggesting that by knowing 
the scope of the problem, and by 
working “with” the industry, nurses will 
be able to avoid complicity in unethical 
promotion [19,20,24,34,49]. 
This optimistic approach belies the 
fact that many nurses are not trained 
in critical appraisal, and appear to 
understand little of the mechanisms 
by which marketing strategies operate. 
Numerous studies have found that 
doctors, regardless of seniority, tend to 
have poor understanding of marketing, 
and of their own vulnerability, decision-
making processes, and conﬂicts of 
interest [57–59]. Nurses are less well-
studied in this regard, but are likely to 
have similar difﬁculties, exacerbated 
by their relatively meagre training in 
pharmacology, statistical inference, and 
critical appraisal.
Understanding the nursing 
perspective. Nursing’s relationship 
to medicine may provide some 
insight into the lack of critical outcry 
in the nursing literature regarding 
pharmaceutical marketing. Direct-to-
consumer advertising and the ubiquity 
of PSRs allow both patients and nurses 
to circumvent the doctor as source of 
authoritative knowledge. Information 
access, however biased, has thus 
become a source of independence for 
nurses and patients alike.
The importance of improving nurse–
doctor relationships may underlie 
the prevalent belief among nurses 
that contact with the pharmaceutical 
industry is beneﬁcial, opening channels 
of communication and providing 
information that enables them to 
interact with doctors on a more even 
footing. It seems likely that the ability 
to seek information from non-medical 
sources may be perceived by some 
nurses as a way to escape traditional 
medical dominance. The perception 
of DTCA as a means to redress this 
power imbalance is captured in the 
commentary of patient advocate 
Charles Inlander, who in 1991 opined 
in Nursing Economic$ that DTCA 
is a tool by which patients could 
circumvent medical paternalism [21]. 
Disdain towards medical dominance 
is also apparent in NP publications, 
whose authors seem to be indignant 
that doctors get “courted” by the 
pharmaceutical industry, while NPs are 
ignored [36,38].
Both the doctor–patient and the 
doctor–nurse relationship have evolved 
in recent years. Ethicists Ezekiel
Emanuel and Linda Emanuel have 
pointed out that the doctor–patient 
interaction has historically been 
paternalistic, where the doctor—with 
superior education and knowledge of 
human biology—was better positioned 
than patients to determine their best 
interest [60]. However, both nurses 
and patients now have greater access 
to information outside the clinical 
encounter, notably including DTCA, 
PSRs, and the Internet, accelerating 
changes to these relationships. 
However, transferring the power 
imbalance from a paternalistic to a 
commercial relationship is hardly the 
last word in liberation. This model 
purports to transfer autonomy, yet 
presents information designed to 
sell, rather than to enable rational 
treatment choices. 
The nursing profession’s 
responsibility. We propose a three-
pronged approach including 
education, clinical policy, and research 
to aid nurses with the challenges of 
pharmaceutical promotion. 
Firstly, nurses require training to 
understand and manage the impact 
of commercial activity, ideally well 
before post-graduate training [32]. 
Nurses already in the work force should 
receive continuing education on the 
range of interests promoted in health 
care, including those motivated by 
proﬁt.
Little in their training provides 
nurses with adequate understanding of 
relevant ﬁelds such as pharmacology, 
epidemiology, public health, 
evidence-based medicine, critical 
appraisal, psychology, social science, 
management, and communications 
studies, to the extent that would allow 
them to reliably understand and 
manage commercial promotion [61]. 
Educational institutions and licensing 
authorities should ensure that their 
students or registrants receive training 
on the inﬂuences of commercialism 
and have unbiased resources to support 
prescribing and clinical decisions. 
Nurses will hopefully come to 
appreciate the vulnerability they share 
with doctors to the charms of the PSR. 
Secondly, institutional guidelines, 
policy, and quality assurance should 
be developed to complement 
such education. The exclusion of 
commercial sponsorship from nursing 
education would leave a gap; careful 
consideration should be made about 
how this gap may be ﬁlled with 
information based on best practice and 
made transparent with respect to its 
inherent biases. 
Policy makers and managers in 
health care must identify and prevent 
the intrusion of external interests 
in clinical decisions. The Stanford 
University initiative to ban PSRs from 
its hospitals is an interesting case 
in point. Whilst on the one hand, it 
makes bold steps towards curtailing 
the presence of the pharmaceutical 
industry in its facilities, on the other, it 
makes no speciﬁc reference to nurses 
[62]. Such policies should carefully 
consider the issues of sponsorship and 
gifts in reference to nurses as well as 
physicians.
The ﬁnal prong in our strategy is to 
gain a better understanding of nurses’ 
role in and inﬂuence on prescribing. 
In the United Kingdom, for example, 
a drive to nurse prescribing is part of 
the professionalisation of nursing, and 
is seen to enhance nursing’s status, 
patient care, and the use of health 
care resources [63]. This prescribing 
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position vis-à-vis the pharmaceutical 
industry as their medical colleagues.
But it is not only prescribing nurses 
who must be the focus of these 
strategies. As we have described above, 
non-subscribing nurses play an under-
appreciated role in prescription and 
administration choices. One of us (AJ), 
an experienced staff nurse, recalls 
guiding new house staff in the choice of 
treatment; the other (DBM) was grateful 
for such guidance as a medical intern. 
Research is required into the 
mechanisms by which nurses inﬂuence 
medical prescribing, and the frequency 
of such inﬂuence in various settings. 
There are a myriad of likely ways in 
which their inﬂuence may be applied, 
from nurse-led clinics where the 
decision to refer is in the nurse’s hands, 
to drug cabinet stocking, treatment 
monitoring and assessment, and 
protocol development. Nurses must 
identify and acknowledge these roles, 
and the enormous responsibility they 
confer, to avoid being a soft target for 
commercial promotion. 
Conclusion
The pharmaceutical industry 
recognises nursing inﬂuence on 
medical prescribing and identiﬁes 
nurses as a marketing target. The 
industry has had its eye on nurses and 
nurse practitioners for over a decade 
[64], and is heavily invested in wooing 
them [65]. Unfortunately, its success 
in this area has been at the expense of 
the health budget, evidence-based care, 
and nursing integrity. All three can and 
must be reclaimed.  
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